Soumaya Ech-Charif
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Soumaya Ech-Charif has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Basma El Khannoussi
Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
4 shared publications - Youssef Mahdi
Department of Pathology and Molecular Pathology, National Institute of Oncology, Rabat, Morocco
3 shared publications - Ihssan Elouarith
Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
2 shared publications - Kadiri Habiba
Pathology Department, Faculty of Medicine and Pharmacy, Oncology National Institute, Mohammed V University, Rabat 10100, Morocco
2 shared publications - Mouna Khmou
Pathology Department, Faculty of Medicine and Pharmacy, Oncology National Institute, Mohammed V University, Rabat 10100, Morocco
2 shared publications - Salma Bekarsabein
Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in Diagnostic Pathology
Decentralized homologous recombination deficiency (HRD) testing in advanced high-grade serous ovarian carcinoma: real-world implementation and molecular profiling from Morocco
Background: Homologous Recombination Deficiency (HRD) testing guides poly (ADP-ribose) polymerase inhibitor (PARPi) therapy in high-grade serous ovarian carcinoma (HGSOC). Centralized commercial assays pose logistical and financial barriers in low- and middle-income countries (LMICs). This study evaluated the pathological validation, clinical implementation, molecular landscape, and feasibility of a decentralized HRD testing platform in North Africa. Materials and methods: This real-world cohort study enrolled 215 advanced HGSOC patients at the National Institute of Oncology in Rabat, Morocco (March 2024–March 2026). Following strict histopathological selection (tumor cellularity ≥ 20%, necrosis < 30%), local genomic profiling utilized an in-house next-generation sequencing (NGS) pipeline (Oncomine Comprehensive Assay Plus) on formalin-fixed paraffin-embedded (FFPE) tumor tissue. HRD positivity was defined by a genomic instability metric (GIM) score ≥ 16. Objective pre-analytical metrics were defined to categorize testing failures. Results: Pre-analytical quality control failed in 57/215 samples (26.5%). DNA degradation ( n = 40, 70.2% of failures) was driven by real-world pre-analytical variability in decentralized workflows, while low DNA yield ( n = 17, 29.8% of failures) was linked to small core needle biopsies with low tumor cellularity or extensive stromal fibrosis. Among 158 evaluable patients, 87 (55.1%) were HRD-positive; 57.5% (50/87) harbored BRCA1/2 mutations and 42.5% (37/87) were BRCA wild-type. HRD prevalence significantly associated with age ( p = 0.017), peaking at 69.4% (50–59 years) and dropping to 32.1% (≥ 70 years). Confrontation of TP53 NGS data with immunohistochemical (IHC) reflex testing on NGS wild-type cases ( n = 27) identified 19 cases with aberrant p53 staining patterns, raising the total rate of p53 abnormalities to 94.9% (150/158). Average turnaround time was three weeks. One test represented 37.1% of the country’s annual Gross Domestic Product (GDP) per capita and over 400% of the monthly minimum wage. Conclusions: Local, decentralized testing is clinically viable in resource-limited settings. Addressing pre-analytical tissue processing quality and conducting formal health-economic evaluations are essential to ensuring sustainable access to precision oncology across LMICs.
- 21 September 2026
- Published by Springer Nature in Diagnostic Pathology
Open AccessDecentralized homologous recombination deficiency (HRD) testing in advanced high-grade serous ovarian carcinoma: real-world implementation and molecular profiling from Morocco
Background: Homologous Recombination Deficiency (HRD) testing guides poly (ADP-ribose) polymerase inhibitor (PARPi) therapy in high-grade serous ovarian carcinoma (HGSOC). Centralized commercial assays pose logistical and financial barriers in low- and middle-income countries (LMICs). This study evaluated the pathological validation, clinical implementation, molecular landscape, and feasibility of a decentralized HRD testing platform in North Africa. Materials and methods: This real-world cohort study enrolled 215 advanced HGSOC patients at the National Institute of Oncology in Rabat, Morocco (March 2024–March 2026). Following strict histopathological selection (tumor cellularity ≥ 20%, necrosis < 30%), local genomic profiling utilized an in-house next-generation sequencing (NGS) pipeline (Oncomine Comprehensive Assay Plus) on formalin-fixed paraffin-embedded (FFPE) tumor tissue. HRD positivity was defined by a genomic instability metric (GIM) score ≥ 16. Objective pre-analytical metrics were defined to categorize testing failures. Results: Pre-analytical quality control failed in 57/215 samples (26.5%). DNA degradation ( n = 40, 70.2% of failures) was driven by real-world pre-analytical variability in decentralized workflows, while low DNA yield ( n = 17, 29.8% of failures) was linked to small core needle biopsies with low tumor cellularity or extensive stromal fibrosis. Among 158 evaluable patients, 87 (55.1%) were HRD-positive; 57.5% (50/87) harbored BRCA1/2 mutations and 42.5% (37/87) were BRCA wild-type. HRD prevalence significantly associated with age ( p = 0.017), peaking at 69.4% (50–59 years) and dropping to 32.1% (≥ 70 years). Confrontation of TP53 NGS data with immunohistochemical (IHC) reflex testing on NGS wild-type cases ( n = 27) identified 19 cases with aberrant p53 staining patterns, raising the total rate of p53 abnormalities to 94.9% (150/158). Average turnaround time was three weeks. One test represented 37.1% of the country’s annual Gross Domestic Product (GDP) per capita and over 400% of the monthly minimum wage. Conclusions: Local, decentralized testing is clinically viable in resource-limited settings. Addressing pre-analytical tissue processing quality and conducting formal health-economic evaluations are essential to ensuring sustainable access to precision oncology across LMICs.
- Open Access
- 18 May 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (5) , rjac233
An unusual variant of lipoma: case report
Osteo-lipoma is a very rare benign tumor with a good prognosis. It is composed mainly of mature fatty tissue with a bony component. The diagnosis is based on the histological study, given the clinical and radiological characters that can simulate other benign or malignant pathologies. Osteosarcoma is the main differential diagnosis. The distinction between these two neoplasms is essential as the basis of the treatment is different. We report the case of a patient with a giant ossifying lipoma independent of bone tissue located in the thigh.
- 18 May 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (5) , rjac233
Open AccessAn unusual variant of lipoma: case report
Osteo-lipoma is a very rare benign tumor with a good prognosis. It is composed mainly of mature fatty tissue with a bony component. The diagnosis is based on the histological study, given the clinical and radiological characters that can simulate other benign or malignant pathologies. Osteosarcoma is the main differential diagnosis. The distinction between these two neoplasms is essential as the basis of the treatment is different. We report the case of a patient with a giant ossifying lipoma independent of bone tissue located in the thigh.
- Open Access
- 30 April 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (4) , rjac116
Breast metastasis 18 years after nephrectomy for renal cell carcinoma: a case report
Metastasis of renal clear cell carcinoma (RCC) to the breast is exceptional. Breast metastases of extra-mammary tumors are rare and usually involve melanoma, lymphoma or leukemia. We report the case of a patient with breast metastasis of renal clear cell carcinoma occurring 18 years after nephrectomy. A history of RCC should always raise suspicion about breast metastasis, a situation that remains exceptional and whose diagnosis relies on anatomopathology.
- 30 April 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (4) , rjac116
Open AccessBreast metastasis 18 years after nephrectomy for renal cell carcinoma: a case report
Metastasis of renal clear cell carcinoma (RCC) to the breast is exceptional. Breast metastases of extra-mammary tumors are rare and usually involve melanoma, lymphoma or leukemia. We report the case of a patient with breast metastasis of renal clear cell carcinoma occurring 18 years after nephrectomy. A history of RCC should always raise suspicion about breast metastasis, a situation that remains exceptional and whose diagnosis relies on anatomopathology.
- Open Access
- 19 February 2022
- Published by Springer Nature in BMC Research Notes
- Vol. 15 (1) , 1-7
Assessment of deep learning algorithms to predict histopathological diagnosis of breast cancer: first Moroccan prospective study on a private dataset
Objective: Breast cancer is a critical public health issue and a leading cause of cancer-related deaths among women worldwide. Its early diagnosis and detection can effectively help in increasing the chances of survival rate. For this reason, the diagnosis and classification of breast cancer using Deep learning algorithms have attracted a lot of attention. Therefore, our study aimed to design a computational approach based on deep convolutional neural networks for an efficient classification of breast cancer histopathological images by using our own created dataset. We collected overall 328 digital slides, from 116 of surgical breast specimens diagnosed with invasive breast carcinoma of non-specific type, and referred to the histopathology department of the National Institute of Oncology in Rabat, Morocco. We used two models of deep neural network architectures in order to accurately classify the images into one of three categories: normal tissue-benign lesions, in situ carcinoma or invasive carcinoma. Results: Both Resnet50 and Xception models achieved comparable results, with a small advantage to Xception extracted features. We reported high degrees of overall correct classification accuracy (88%), and sensitivity (95%) for detection of carcinoma cases, which is important for diagnostic pathology workflow in order to assist pathologists for diagnosing breast cancer with precision. The results of the present study showed that the designed classification model has a good generalization performance in predicting diagnosis of breast cancer, in spite of the limited size of the data. To our knowledge, this approach can be highly compared with other common methods in the automated analysis of breast cancer images reported in literature.
- 19 February 2022
- Published by Springer Nature in BMC Research Notes
- Vol. 15 (1) , 1-7
Open AccessAssessment of deep learning algorithms to predict histopathological diagnosis of breast cancer: first Moroccan prospective study on a private dataset
Objective: Breast cancer is a critical public health issue and a leading cause of cancer-related deaths among women worldwide. Its early diagnosis and detection can effectively help in increasing the chances of survival rate. For this reason, the diagnosis and classification of breast cancer using Deep learning algorithms have attracted a lot of attention. Therefore, our study aimed to design a computational approach based on deep convolutional neural networks for an efficient classification of breast cancer histopathological images by using our own created dataset. We collected overall 328 digital slides, from 116 of surgical breast specimens diagnosed with invasive breast carcinoma of non-specific type, and referred to the histopathology department of the National Institute of Oncology in Rabat, Morocco. We used two models of deep neural network architectures in order to accurately classify the images into one of three categories: normal tissue-benign lesions, in situ carcinoma or invasive carcinoma. Results: Both Resnet50 and Xception models achieved comparable results, with a small advantage to Xception extracted features. We reported high degrees of overall correct classification accuracy (88%), and sensitivity (95%) for detection of carcinoma cases, which is important for diagnostic pathology workflow in order to assist pathologists for diagnosing breast cancer with precision. The results of the present study showed that the designed classification model has a good generalization performance in predicting diagnosis of breast cancer, in spite of the limited size of the data. To our knowledge, this approach can be highly compared with other common methods in the automated analysis of breast cancer images reported in literature.
- 1 January 2008
- Vol. 129, 337-40
[Solitary myofibroma of the mandible: a case report].
Infantile myofibromatosis (IMF) are integrated in the group of fibromatosis juvenile-type which are benign mesenchymal lesions, characterized morphologically by a proliferation of fibroblasts and myofibroblastes, with perivascular pattern. Through a case of solitary myofibroma of the mandible, we will emphasize anatomo-clinical features and differential diagnosis. We report a case illustrating solitary myofibroma of the mandible in 18 month old infant. The histological diagnosis was done on the identification of two separate components, a fascicular myofibroblastic pattern at the periphery with a hemangiopericytoma like pattern in the centre. Both components positive for alpha-smooth muscle actin and vimentin. Solitary IMF is characterised by a single lesion arising from cutaneous, bony or soft tissues. Morphological and immunohistochemical examination allow the diagnosis of the typical form. The differential diagnosis includes other benign spindle cells tumours. The prognosis is excellent with possibility to regress spontaneously.
- 1 January 2008
- Vol. 129, 337-40
[Solitary myofibroma of the mandible: a case report].
Infantile myofibromatosis (IMF) are integrated in the group of fibromatosis juvenile-type which are benign mesenchymal lesions, characterized morphologically by a proliferation of fibroblasts and myofibroblastes, with perivascular pattern. Through a case of solitary myofibroma of the mandible, we will emphasize anatomo-clinical features and differential diagnosis. We report a case illustrating solitary myofibroma of the mandible in 18 month old infant. The histological diagnosis was done on the identification of two separate components, a fascicular myofibroblastic pattern at the periphery with a hemangiopericytoma like pattern in the centre. Both components positive for alpha-smooth muscle actin and vimentin. Solitary IMF is characterised by a single lesion arising from cutaneous, bony or soft tissues. Morphological and immunohistochemical examination allow the diagnosis of the typical form. The differential diagnosis includes other benign spindle cells tumours. The prognosis is excellent with possibility to regress spontaneously.